ACHV Quote, Financials, Valuation and Earnings

Electromed has a net margin of -- compared to Achieve Life Sciences's net margin of 10.05%. Achieve Life Sciences's return on equity of -- beat Electromed's return on equity of 15.62%.

Achieve Life Sciences has a consensus price target of $16.44, signalling upside risk potential of 344.44%. On the other hand Electromed has an analysts' consensus of -- which suggests that it could grow by 7.53%. Given that Achieve Life Sciences has higher upside potential than Electromed, analysts believe Achieve Life Sciences is more attractive than Electromed.

Achieve Life Sciences has a beta of 1.665, which suggesting that the stock is 66.463% more volatile than S&P 500. In comparison Electromed has a beta of 0.314, suggesting its less volatile than the S&P 500 by 68.592%.

Achieve Life Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Achieve Life Sciences pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Achieve Life Sciences quarterly revenues are --, which are smaller than Electromed quarterly revenues of $14.7M. Achieve Life Sciences's net income of -$12.5M is lower than Electromed's net income of $1.5M. Notably, Achieve Life Sciences's price-to-earnings ratio is -- while Electromed's PE ratio is 42.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Achieve Life Sciences is -- versus 4.80x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Myomo has a net margin of -- compared to Achieve Life Sciences's net margin of -10.5%. Achieve Life Sciences's return on equity of -- beat Myomo's return on equity of -84.04%.

Achieve Life Sciences has a consensus price target of $16.44, signalling upside risk potential of 344.44%. On the other hand Myomo has an analysts' consensus of -- which suggests that it could grow by 16.34%. Given that Achieve Life Sciences has higher upside potential than Myomo, analysts believe Achieve Life Sciences is more attractive than Myomo.

Achieve Life Sciences has a beta of 1.665, which suggesting that the stock is 66.463% more volatile than S&P 500. In comparison Myomo has a beta of 1.719, suggesting its more volatile than the S&P 500 by 71.909%.

Achieve Life Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Achieve Life Sciences pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

Achieve Life Sciences quarterly revenues are --, which are smaller than Myomo quarterly revenues of $9.2M. Achieve Life Sciences's net income of -$12.5M is lower than Myomo's net income of -$966.4K. Notably, Achieve Life Sciences's price-to-earnings ratio is -- while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Achieve Life Sciences is -- versus 9.63x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

Senseonics Holdings has a net margin of -- compared to Achieve Life Sciences's net margin of -562.42%. Achieve Life Sciences's return on equity of -- beat Senseonics Holdings's return on equity of -445.19%.

Achieve Life Sciences has a consensus price target of $16.44, signalling upside risk potential of 344.44%. On the other hand Senseonics Holdings has an analysts' consensus of -- which suggests that it could grow by 219.81%. Given that Achieve Life Sciences has higher upside potential than Senseonics Holdings, analysts believe Achieve Life Sciences is more attractive than Senseonics Holdings.

Achieve Life Sciences has a beta of 1.665, which suggesting that the stock is 66.463% more volatile than S&P 500. In comparison Senseonics Holdings has a beta of 0.636, suggesting its less volatile than the S&P 500 by 36.39%.

Achieve Life Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Senseonics Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Achieve Life Sciences pays -- of its earnings as a dividend. Senseonics Holdings pays out -- of its earnings as a dividend.

Achieve Life Sciences quarterly revenues are --, which are smaller than Senseonics Holdings quarterly revenues of $4.3M. Achieve Life Sciences's net income of -$12.5M is higher than Senseonics Holdings's net income of -$24M. Notably, Achieve Life Sciences's price-to-earnings ratio is -- while Senseonics Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Achieve Life Sciences is -- versus 13.89x for Senseonics Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -- compared to Achieve Life Sciences's net margin of -17.98%. Achieve Life Sciences's return on equity of -- beat Xtant Medical Holdings's return on equity of -35.98%.

Achieve Life Sciences has a consensus price target of $16.44, signalling upside risk potential of 344.44%. On the other hand Xtant Medical Holdings has an analysts' consensus of -- which suggests that it could grow by 326.95%. Given that Achieve Life Sciences has higher upside potential than Xtant Medical Holdings, analysts believe Achieve Life Sciences is more attractive than Xtant Medical Holdings.

Achieve Life Sciences has a beta of 1.665, which suggesting that the stock is 66.463% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.343, suggesting its less volatile than the S&P 500 by 65.673%.

Achieve Life Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Achieve Life Sciences pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Achieve Life Sciences quarterly revenues are --, which are smaller than Xtant Medical Holdings quarterly revenues of $27.9M. Achieve Life Sciences's net income of -$12.5M is lower than Xtant Medical Holdings's net income of -$5M. Notably, Achieve Life Sciences's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Achieve Life Sciences is -- versus 0.61x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.